Johnson & Johnson (JNJ)vsNuvalent Inc (NUVL)
JNJ
Johnson & Johnson
$231.29
+0.82%
HEALTHCARE · Cap: $567.28B
NUVL
Nuvalent Inc
$90.95
-3.27%
HEALTHCARE · Cap: $9.75B
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
JNJ
Buy57
out of 100
Grade: C
NUVL
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-67.8%
Fair Value
$136.12
Current Price
$231.29
$95.17 premium
Intrinsic value data unavailable for NUVL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : NUVL
The primary concerns for NUVL are Revenue Growth, EPS Growth, Profit Margin.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NUVL is a value play — different risk/reward profiles.
NUVL carries more volatility with a beta of 1.15 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 25/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is an innovative clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to provide cutting-edge treatment solutions that specifically target genetic mutations driving tumor growth, ultimately enhancing patient outcomes and minimizing adverse effects. With a strong pipeline of highly selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating a steadfast commitment to revolutionizing cancer treatment and improving patient care across the oncology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?